- Edoxaban - a new xaban on the scene2017 | First Faculty of Medicine, Third Faculty of Medicine
- Edoxaban - medication profile2013 | Publication without faculty affiliation
- Edoxaban - new FXa inhibitor2017 | Publication without faculty affiliation
- ENSURE-AF trial: edoxaban and elective cardioversion2019 | First Faculty of Medicine
- Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism2013 | Second Faculty of Medicine
- New direct oral anticoagulants2016 | Publication without faculty affiliation
- Anticoagulation therapy in 20152015 | First Faculty of Medicine
- Anticoagulation therapy in 20152016 | Publication without faculty affiliation
- Novel oral anticoagulants - the advantages and drawbacks of the therapy2015 | Third Faculty of Medicine
- Edoxaban for treatment of venous thromboembolism in patients with cancer Rationale and design of the Hokusai VTE-cancer study2015 | Second Faculty of Medicine
- Anticoagulant therapy in the elderly2018 | First Faculty of Medicine, Third Faculty of Medicine
- Cancer-associated thromboembolism2023 | First Faculty of Medicine
- Bleeding complications of antithrombotic therapy - prevention is essential2020 | Publication without faculty affiliation
- Léčba edoxabanem oproti léčbě warfarinem u pacientů s fibrilací síní - studie ENGAGE AF-TIMI 482016 | First Faculty of Medicine
- Prescribing patterns and outcomes of edoxaban in atrial fibrillation: One-year data from the Global ETNA-AF programme2022 | Faculty of Medicine in Pilsen
- What we expect from anticoagulant therapy in 20142014 | Publication without faculty affiliation
- Anticoagulation therapy 20162016 | Second Faculty of Medicine
- Anticoagulation therapy in the elderly2016 | Second Faculty of Medicine
- 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Translation of the document prepared by the Czech Society of Cardiology2023 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Cost-effectiveness analysis of first-line NOAC prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation2019 | First Faculty of Medicine, Second Faculty of Medicine
- Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry2023 | Faculty of Medicine in Pilsen
- The potential use of laboratory monitoring during individualizing the dosage of direct oral anticoagulants - a literature review2023 | Faculty of Pharmacy in Hradec Králové
- Antikoagulační léčba hluboké žilní trombózy a plicní embolie2017 | Second Faculty of Medicine
- Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries2021 | Faculty of Medicine in Pilsen
- Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Implantation in Patients Without Indications for Chronic Oral Anticoagulation: A systematic review and network meta-analysis of randomized controlled trials2023 | Third Faculty of Medicine
- Beriplex(R), four-factor prothrombin complex concentrate2016 | Publication without faculty affiliation
- Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry2023 | Publication without faculty affiliation
- Postavení přímých orálních antikoagulancií v léčbě žilní trombózy (up to date 2018)2018 | First Faculty of Medicine
- Anticoagulation therapy in cancer associated thromboembolism - new studies, new guidelines2020 | Faculty of Medicine in Pilsen
- Dabigatran in the prevention of stroke in patients with atrial fibrilation2011 | First Faculty of Medicine, Third Faculty of Medicine